BRPI0515624A - invenção referente ao glp-1 e à exendina - Google Patents

invenção referente ao glp-1 e à exendina

Info

Publication number
BRPI0515624A
BRPI0515624A BRPI0515624-6A BRPI0515624A BRPI0515624A BR PI0515624 A BRPI0515624 A BR PI0515624A BR PI0515624 A BRPI0515624 A BR PI0515624A BR PI0515624 A BRPI0515624 A BR PI0515624A
Authority
BR
Brazil
Prior art keywords
glu
ser
gly
leu
ala
Prior art date
Application number
BRPI0515624-6A
Other languages
English (en)
Inventor
Martin Gotthardt
Martin Behe
Thomas Behr
J Burkhard Goeke
Original Assignee
Univ Marburg Philipps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Marburg Philipps filed Critical Univ Marburg Philipps
Publication of BRPI0515624A publication Critical patent/BRPI0515624A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Food Science & Technology (AREA)

Abstract

"INVENçãO REFERENTE AO GLP-1 E à EXENDINA". Na presente invenção, são providos peptídeos derivados de GLP-1 (glucagon-like peptídeo-1) e exendina-3 e/ou exendina-4, que se ligam ao receptor de GLP-1 e podem ser utilizados marcados ou não marcados para produção de um agente para diagnóstico e terapia de doenças benignas e malignas nas quais a expressão de GLP-1 desempenha um papel.
BRPI0515624-6A 2004-09-03 2005-08-26 invenção referente ao glp-1 e à exendina BRPI0515624A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004043153A DE102004043153B4 (de) 2004-09-03 2004-09-03 Erfindung betreffend GLP-1 und Exendin
PCT/DE2005/001503 WO2006024275A2 (de) 2004-09-03 2005-08-26 Erfindung betreffend glp-1 und exendin

Publications (1)

Publication Number Publication Date
BRPI0515624A true BRPI0515624A (pt) 2008-07-29

Family

ID=35970651

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515624-6A BRPI0515624A (pt) 2004-09-03 2005-08-26 invenção referente ao glp-1 e à exendina

Country Status (16)

Country Link
US (2) US8268781B2 (pt)
EP (3) EP1784422B1 (pt)
JP (1) JP5047795B2 (pt)
KR (1) KR101237152B1 (pt)
CN (3) CN101010340B (pt)
AT (1) ATE486090T1 (pt)
AU (1) AU2005279537C1 (pt)
BR (1) BRPI0515624A (pt)
CA (2) CA2578252A1 (pt)
DE (2) DE102004043153B4 (pt)
HR (1) HRP20110061T1 (pt)
MX (1) MX2007002455A (pt)
NO (1) NO20071592L (pt)
PL (2) PL2070946T3 (pt)
RU (3) RU2420536C2 (pt)
WO (1) WO2006024275A2 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007013655A (es) * 2005-05-05 2008-01-24 Cadila Healthcare Ltd Nuevos compuestos como agonistas glp-i.
EP4049673A1 (en) 2007-01-08 2022-08-31 The Trustees of the University of Pennsylvania Glp-1 receptor antagonist for use in the treatment of post-prandial hypoglycemia or congenital hyperinsulinism
JP4642920B2 (ja) * 2008-09-20 2011-03-02 国立大学法人京都大学 膵島イメージング用分子プローブ前駆体及びその使用
CA3016451A1 (en) 2008-10-17 2010-04-22 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a glp-1 agonist
WO2010118034A2 (en) * 2009-04-06 2010-10-14 Board Of Regents, The University Of Texas System Cyclic peptide analogues for non-invasive imaging of pancreatic beta-cells
CN101987868B (zh) * 2009-07-30 2013-09-04 江苏豪森医药集团有限公司 Glp-1类似物的衍生物或其可药用盐和用途
KR101321461B1 (ko) * 2009-08-10 2013-10-29 아크레이 가부시키가이샤 췌도 이미징용 분자 프로브 및 그 전구체, 및 그들의 사용
WO2011027584A1 (ja) * 2009-09-04 2011-03-10 国立大学法人京都大学 膵島イメージング用分子プローブ及びその使用
KR101525473B1 (ko) * 2009-09-30 2015-06-03 고쿠리츠 다이가쿠 호진 교토 다이가쿠 췌도 이미징용 분자 프로브 및 그 사용
KR101772372B1 (ko) 2009-11-13 2017-08-29 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
RU2537239C2 (ru) 2009-11-13 2014-12-27 Санофи-Авентис Дойчланд Гмбх Фармацевтическая композиция, включающая агонист glp-1, инсулин и метионин
EP2510951B1 (en) 2009-12-10 2016-07-13 Kyoto University Molecular probe for imaging of pancreatic islet, and use thereof
CN101875700B (zh) * 2010-04-09 2012-09-26 无锡和邦生物科技有限公司 一种增加促胰岛素分泌肽融合蛋白生物活性的方法
HUE031181T2 (en) 2010-08-30 2017-06-28 Sanofi Aventis Deutschland Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes
US9278146B2 (en) 2010-10-08 2016-03-08 Kyoto University Peptide derivative and use of the same
WO2012121746A2 (en) 2011-03-09 2012-09-13 The General Hospital Corporation Imaging beta cell mass
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9944687B2 (en) 2011-07-04 2018-04-17 Imperial Innovations Limited Compounds and their effects on feeding behaviour
SI2750699T1 (sl) 2011-08-29 2015-11-30 Sanofi-Aventis Deutschland Gmbh Farmacevtska kombinacija, za uporabo pri glikemični kontroli pri pacientih, ki imajo sladkorno bolezen tipa 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US8901484B2 (en) * 2012-04-27 2014-12-02 Sanofi-Aventis Deutschland Gmbh Quantification of impurities for release testing of peptide products
WO2013182217A1 (en) * 2012-04-27 2013-12-12 Sanofi-Aventis Deutschland Gmbh Quantification of impurities for release testing of peptide products
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
TWI617574B (zh) * 2012-12-11 2018-03-11 梅迪繆思有限公司 用於治療肥胖之升糖素與ｇｌｐ－１共促效劑
ES2653765T3 (es) 2012-12-21 2018-02-08 Sanofi Agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/glucagón
CN103344764B (zh) * 2013-06-19 2014-11-26 天津美德太平洋科技有限公司 胰高血糖素样肽-1生物学活性检测试剂及检测方法和试剂盒
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
DE102014112747A1 (de) * 2014-09-04 2016-03-10 Eberhard Karls Universität Tübingen Medizinische Fakultät Verwendung eines Quinoxalinderivats in einem bildgebenden Verfahren
HRP20230470T1 (hr) 2014-12-12 2023-07-21 Sanofi-Aventis Deutschland Gmbh Formulacija fiksnog omjera inzulin glargin/liksisenatid
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
RS62368B1 (sr) * 2015-05-22 2021-10-29 Univ Leland Stanford Junior Lečenje postbarijatrijske hipoglikemije eksendinom(9-39)
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
HUE053079T2 (hu) 2015-12-14 2021-06-28 Antaros Medical Ab Képalkotási célokból kelátképzõ részt tartalmazó szelektív glükagonreceptor-agonisták
US10653753B2 (en) 2016-03-04 2020-05-19 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
JP2019535734A (ja) 2016-11-21 2019-12-12 アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． エキセンディン（９−３９）の緩衝製剤
WO2021198229A1 (en) 2020-03-31 2021-10-07 Antaros Medical Ab Selective gip receptor agonists comprising a chelating moiety for imaging and therapy purposes

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2070329T3 (es) * 1989-07-20 1995-06-01 Sandoz Ltd Derivados de polipeptidos.
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5574008A (en) * 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
KR100600457B1 (ko) * 1996-06-05 2006-07-13 로셰 디아그노스틱스 게엠베하 엑센딘 유사체, 이의 제조방법 및 이를 함유한 약제
EP1056775B1 (en) * 1998-02-27 2010-04-28 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
EP1056774A1 (en) * 1998-02-27 2000-12-06 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
US7259136B2 (en) * 1999-04-30 2007-08-21 Amylin Pharmaceuticals, Inc. Compositions and methods for treating peripheral vascular disease
NZ514916A (en) * 1999-04-30 2004-06-25 Amylin Pharmaceuticals Inc Exendins and exendin agonists linked to polyethylene glycol polymers
PT1105409E (pt) * 1999-05-17 2006-07-31 Conjuchem Inc Proteccao de peptidos terapeuticos endogenos da actividade de peptidases por conjugacao a componentes do sangue
ATE252601T1 (de) * 1999-05-17 2003-11-15 Conjuchem Inc Lang wirkende insulinotrope peptide
US6528486B1 (en) * 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
EP1076066A1 (en) * 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
DK1246638T4 (da) * 2000-01-10 2014-09-22 Amylin Pharmaceuticals Llc Anvendelse af extendiner og agonister deraf til behandlingen af hypertriglyceridæmi
US7514078B2 (en) * 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US20030232761A1 (en) * 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
US7544657B2 (en) * 2002-10-02 2009-06-09 Zealand Pharma A/S Stabilized Exendin-4 compounds
KR20050049525A (ko) * 2002-10-11 2005-05-25 가부시키가이샤산와카가쿠켄큐쇼 Ｇｌｐ-1 유도체 및 그의 경점막 흡수형 제제

Also Published As

Publication number Publication date
AU2005279537B2 (en) 2012-02-16
CA2797666A1 (en) 2006-03-09
EP1784422A2 (de) 2007-05-16
AU2005279537C1 (en) 2012-07-05
KR20070093960A (ko) 2007-09-19
PL2070946T3 (pl) 2013-09-30
CN102304179A (zh) 2012-01-04
WO2006024275A3 (de) 2006-11-30
HRP20110061T1 (hr) 2011-02-28
NO20071592L (no) 2007-05-29
ATE486090T1 (de) 2010-11-15
EP2301962A2 (de) 2011-03-30
JP5047795B2 (ja) 2012-10-10
RU2010148447A (ru) 2012-06-10
CN102358752B (zh) 2014-07-30
EP2301962B1 (de) 2013-10-30
US20090180953A1 (en) 2009-07-16
EP2070946A3 (de) 2009-09-09
AU2005279537A1 (en) 2006-03-09
PL2301962T3 (pl) 2014-05-30
MX2007002455A (es) 2007-10-10
US20130095037A1 (en) 2013-04-18
RU2489443C2 (ru) 2013-08-10
KR101237152B1 (ko) 2013-03-04
CN102358752A (zh) 2012-02-22
US8268781B2 (en) 2012-09-18
RU2486197C2 (ru) 2013-06-27
WO2006024275A2 (de) 2006-03-09
EP2301962A3 (de) 2011-11-02
RU2420536C2 (ru) 2011-06-10
DE502005010449D1 (de) 2010-12-09
DE102004043153B4 (de) 2013-11-21
JP2008511557A (ja) 2008-04-17
EP2070946A2 (de) 2009-06-17
DE102004043153A1 (de) 2006-03-23
CA2578252A1 (en) 2006-03-09
RU2010148446A (ru) 2012-06-10
EP2070946B1 (de) 2013-05-29
EP1784422B1 (de) 2010-10-27
RU2007112115A (ru) 2008-10-10
CN101010340A (zh) 2007-08-01
CN101010340B (zh) 2012-11-28

Similar Documents

Publication Publication Date Title
BRPI0515624A (pt) invenção referente ao glp-1 e à exendina
RU2019122785A (ru) Комбинации соединения на основе fgf21/агониста glp-1r с оптимизированным соотношением активности
PE20220938A1 (es) Compuestos agonistas de gipr
PH12021550154A1 (en) Gip/glp1 co-agonist compounds.
NO20063436L (no) Intranasal administrasjon av glukose-regulerende peptider
PE20170954A1 (es) Compuestos co-agonistas de gip y glp-1
ATE448247T1 (de) Fusionspolypeptide vom glp-1 (glucagon-like peptide-1) mit erhöhten peptidaseresistenz
EA200300644A1 (ru) Слитые белки glp-1
DK1523325T3 (da) Fremgangsmåder og sammensætninger til behandling af polycystisk ovariesyndrom
PA8738401A1 (es) Proteinas de fusion de exendina
RU2010101232A (ru) Производное инсулинотропного пептида, содержащее модифицированную n-концевую аминокислоту
AR022368A1 (es) Procedimiento para administrar peptidos insulinotropicos
DK1761553T3 (da) MHC molecule-binding tumor-associated peptides
HRP20020996B1 (en) Glucagon-like peptide-1 analogs
JP2004509079A5 (pt)
WO2007028394A3 (en) Use of a glp-1 molecule for treatment of biliary dyskinesia and/or biliary pain/discomfort
MX2023002906A (es) Agonistas duales glp-1/gip.
MX2022009149A (es) Compuestos coagonistas de gip/glp1.
US20180162920A1 (en) Protease-resistant lipidated glp-1 analogs
NO20070615L (no) Fremgangsmate for fremstilling av aminosyrer anvendelige ved fremstilling av peptidreseptormodulatorer.
EA200800181A1 (ru) Фармацевтическая композиция glp-1
AU2017277594A1 (en) Protease-resistant mono-lipidated peptides
EA202092891A1 (ru) Соединения-коагонисты gip/glp1
ECSP993116A (es) Procedimiento para administrar peptidos insulinotropicos
AR060795A1 (es) Moleculas quimericas fusionadas a matrilina 1, de uso terapeutico

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.